- Home
- Profiles
Stephen Ward, MD, PhD
Anatomic Pathology and Clinical Pathology
- About Me
- Clinical Focus
- Education & Certifications
- Insurance
- Publications
- Industry Relationships
About Me
Language
Position
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- New York Eye and Ear Infirmary of Mount Sinai
- Mount Sinai West
About Me
Language
Position
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- New York Eye and Ear Infirmary of Mount Sinai
- Mount Sinai West
Clinical Focus
- Adenomas
- Amyloidosis
- Autoimmune Hepatitis
- Bile Duct Diseases
- Biopsy
- Cholangiocarcinoma
- Cirrhosis
- Colon Polyps
- Colorectal Cancer
Show More
- Adenomas
- Amyloidosis
- Autoimmune Hepatitis
- Bile Duct Diseases
- Biopsy
- Cholangiocarcinoma
- Cirrhosis
- Colon Polyps
- Colorectal Cancer
- Esophageal Cancer
- Fatty Liver Disease
- Hemangioma
- Hepatitis B
- Hepatitis C
- Hepatocellular Carcinoma
- IBD
- Kidney Transplantation
- Liver Cancer
- Liver Transplant
- Peptic Ulcer
- Small Bowel Resection
- Ulcerative Colitis
Education
MD, University of Rochester Nurse Midwifery Program
PhD, University of Maryland
Residency, Pathology - Anatomic/Pathology - Clinical
Bellevue Hospital Center
Insurance Information
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Antonio D'Alessio, Bernardo Stefanini, Julia Blanter, Benjamin Adegbite, Fionnuala Crowley, Vincent Yip, Sarah Slater, Claudia Angela Maria Fulgenzi, Ciro Celsa, Giulia Francesca Manfredi, Madhava Pai, Robert D. Goldin, Stephen C. Ward, Maria Isabel Fiel, Daniel H. Shu, Yung Yeh Su, Alessio Cortellini, Marina Baretti, Robert Anders, Mark Yarchoan, Chiun Hsu, Thomas U. Marron, David J. Pinato. The Lancet Oncology
- Single-cell RNA sequencing data identify a conserved population of metallothionein-expressing macrophages that may be ubiquitous in vital human organs. Joseph A. Daccache, Francis Eng, Lei Cao, Ning Ma, Stephen C. Ward, Thomas Schiano, Mark Miller, Daniel Herron, Anthony V. Azzara, Steven S. Pullen, Paolo Guarnieri, Costica Aloman, Andrea D. Branch. Clinical and Translational Discovery
- A large-scale retrospective study enabled deep-learning based pathological assessment of frozen procurement kidney biopsies to predict graft loss and guide organ utilization. Zhengzi Yi, Caixia Xi, Madhav C. Menon, Paolo Cravedi, Fasika Tedla, Alan Soto, Zeguo Sun, Keyu Liu, Jason Zhang, Chengguo Wei, Man Chen, Wenlin Wang, Brandon Veremis, Monica Garcia-barros, Abhishek Kumar, Danielle Haakinson, Rachel Brody, Evren U. Azeloglu, Lorenzo Gallon, Philip O'Connell, Maarten Naesens, Ron Shapiro, Robert B. Colvin, Stephen Ward, Fadi Salem, Weijia Zhang. Kidney International
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Ward during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Astrazeneca
- Martin Clearwater & Bell LLP
- Intercept Pharm
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Ward during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Astrazeneca
- Martin Clearwater & Bell LLP
- Intercept Pharm
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.